A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

Type 2 Diabetes Patients Clinical Trial

Official title:
A Phase 1B, Randomized, Double-Blind, Placebo-Controlled Trial To Assess The Efficacy And Safety Of 4-Week Administration Of Multiple Oral Doses Of PF-04620110 In Type 2 Diabetes Mellitus Subjects With Insufficient Glycemic Control On Metformin

Status Completed

Clinical Trial Summary

PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in T2DM patients.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01298518
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 1
Start date	February 2011
Completion date	May 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03087032` - Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)	Phase 4
Withdrawn	`NCT04662164` - A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin	Phase 1/Phase 2
Not yet recruiting	`NCT01418911` - Attachment Style of Type 2 Diabetics, and Cognitive, Social and Emotional Variables as Explanatory Factors of Adherence to Self-care Behavior and Diabetes Control	N/A